New Antiretroviral Drugs in the Pandemic
DOI:
https://doi.org/10.14456/2022s10303Keywords:
New, Antiretroviral drugs, Pandemic, HIV, Long-actingAbstract
The pandemic of coronavirus disease-19 (COVID-19) has impacted the care of people living with human immunodeficiency virus (HIV) and HIV prevention in several ways. Locking down and limiting transportation to slow down COVID-19 transmission can cause difficulty accessing and non-compliance to daily-dosing antiretroviral drugs (ARVs). The new formu-lations of ARVs, including long-acting ones administered as injections and implants are being approved and developed for HIV treatment and prevention. Intramuscular cabotegravir and rilpivirine co-formulation is approved by the US Food and Drug Administration for HIV treatment in virologically suppressed adults on a stable regimen, while intramuscular cabotegravir is approved for HIV pre-exposure prophylaxis. Other long-acting drugs, such as lenacapavir and islatravir have currently been developed and studied for HIV treatment and/or prevention. This present article concisely reviews the current knowledge on these new ARVs and their implications, which may serve as novel regimens for use during the current and future pandemics.
Downloads
References
Disruption in HIV, hepatitis and STI services due to COVID-19 2020.World Health Organization. https://www.who.int/docs/defaultsource/hiv-hq/disruption-hiv-hepatitissti-services-due-to-covid19.pdf?sfvrsn=5f78b742_6. Published 2020. Accessed March 6, 2022.
Gatechompol S, Avihingsanon A, Putcharoen O, Ruxrungtham K, Kuritzkes DR. COVID-19 and HIV infection co-pandemics and their
impact: a review of the literature. AIDS Res Ther. 2021;18:28.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adultand-AdolescentGL.pdf. Updated 2022. Accessed March 6, 2022.
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization. https://www.who.int/publications/i/item/9789240031593. Updated 2022. Accessed March 6, 2022.
Byrd KK, Hou JG, Hazen R, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr. 2019;82:245-251.
Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340-348.
Dube K,Campbell DM, Perry KE, et al. Reasons people living with HIV might prefer oral daily antiretroviral therapy, long-acting formulations, or future HIV remission options. AIDS Res Hum Retroviruses. 2020;36:1054-1058.
Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77:290-302.
Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of longacting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:e1002690.
FDA approves first injectable treatment for HIV pre-exposure prevention. The United States Food and Drug Administration. https://
www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention. Updated 2021.
Accessed March 12, 2022.
Ferretti F, Boffito M. Rilpivirine long-acting for the prevention and treatment of HIV infection. Curr Opin HIV AIDS. 2018;13:300-307
FDAapproves first extended-release, injectable drug regimen for adults living with HIV. The United States Food and Drug Administration. https://www.fda.gov/news-events/pressannouncements/fda-approves-first-extendedrelease-injectable-drug-regimen-adults-living-hiv. Updated 2021. Accessed March 12, 2022.
Sager J, Begley R, Rhee M, et al. Safety and PK of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor. Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7, 2019. Seattle, Washington, US. https://www.natap.org/2019/CROI/croi_43.htm. Accessed March 12, 2022.
Begley R, Lutz J, Dvory-Sobol H, et al. Clinical evaluation of drug interactions with oral lenacapavir and probe drugs. Conference on
Retroviruses and Opportunistic Infections (CROI); March 6-10, 2021. Levin, New Zealand. https://www.natap.org/2021/CROI/croi_26.htm. Accessed March 12, 2022.
Markowitz M, Grobler JA. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. Curr Opin HIV AIDS. 2020;15:27-32.
Schurmann D, Rudd DJ, Zhang S, et al. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. Lancet HIV. 2020;7:164-172.
Sharp M, Corp D. Merck provides update on phase 2 clinical trial of once-weekly investigational combination of MK-8507 and islatravir for the treatment of people living with HIV-1. https://www.merck.com/news/merck-provides-update-on-phase-2-clinicaltrial-of-once-weekly-investigational-combination-of-mk-8507-and-islatravir-for-the-treatment-of-people-living-with-hiv-1/. Accessed
May 27, 2022.
Welda ED, Flexner C. Long-acting implantsto treat and prevent HIV infection. J Antimicrob Chemother. 2017;72:3008-3011.
Matthews RP, Zang X, Barrett S, et al. Next generation islatravir implants projected to provide yearly HIV prophylaxis. Conference
on Retroviruses and Opportunistic Infections (CROI); March 6-10, 2021 (virtual).
Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379:645-654.
Gulick RM, Flexner C. Long-acting HIV drugs for treatment and prevention. Annu Rev Med. 2019;70:137-150.
Czarnogorski M, D’Amico R, Benn P, et al. Summary of COVID-related impact on cabotegravir and rilpivirine long-acting (CAB+RPV LA) dosing across the six ongoing global phase IIb and IIIb clinical trials. https://www.contagionlive.com/view/covid-19s-effect-on-clinical-trials-of-long-acting-cabotegravir-and-rilpivirine-for-hiv-infection. Accessed May 28, 2022.
Czarnogorski M, Garris C, Stassek L, et al. CAB+RPV LA implementation outcomes and acceptability of monthly clinic visits improved during COVID-19 pandemic across US healthcare clinics (CUSTOMIZE: hybrid III implementation-effectiveness study). The 11th International AIDS Society Conference on HIV Science; July 18-21, 2021.
Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499-1510.
Orkin C,Arasteh K, Gorgolas Hernandez-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124-1135.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112-1123.
Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, noninferiority study. Lancet. 2021;396:1994-2005.
Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.
Delany-Moretlwe S, Hughes J, Bock P, et al. Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgenderwomen: interim results from HPTN 084. HIV Research for Prevention Conference (HIVR4P); January 27 - February 4, 2021 (virtual).
Molina JM, Segal-Maurer S, Stellbrink HJ, et al. Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study). The 11th International AIDS Society Conference on HIV Science; July 18-21, 2021.
Gupta SK, Berhe M, Crofoot G, et al. Longacting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen
in treatment-naive people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE). The 11th InternationalAIDS Society Conference on HIV Science;July 18-21, 2021.
Sharp M, Corp D. A phase 3, randomized, active-controlled, double-blind clinical study to evaluate the efficacy and safety of oral islatravir once-monthly as preexposure prophylaxis in cisgender women at high risk for HIV-1 infection. Clinical Trial Registration NCT04644029. https://clinicaltrials.gov/ct2/show/NCT04644029. Updated 2021.Accessed March 8, 2022.
Sharp M, Corp D. A Phase 3, randomized, active-controlled, double-blind clinical study to evaluate the efficacy and safety of oral islatravir once-monthly as preexposure prophylaxisin cisgender men and transgender women who have sex with men, and are at high risk for HIV-1 infection. Clinical Trial Registration NCT04652700. https://clinicaltrials.gov/ct2/show/NCT04652700. Updated 2021.Accessed March 8, 2022.
Sharp M, Corp D. A phase 2a, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of oral MK8591 once-monthly in participants at low- risk for HIV-1 infection. Clinical Trial Registration NCT04003103. https://clinicaltrials.gov/ct2/show/NCT04003103. Updated 2020.Accessed March 8, 2022.
Sharp M, Corp D. A phase 2a, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of a
radiopaque matrix MK-8591 implant in participants at low-risk for HIV-1 infection. Clinical Trial Registration NCT05115838. https://clinicaltrials.gov/ct2/show/NCT05115838. Updated 2021. Accessed March 8, 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Asian Medical Journal and Alternative Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
